When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions The Wolverine Drug Ortho Rhode Island Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved drugs with Peptides, Drugs And Supplements: Science, Risks, And Alternatives Los Angeles Times